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ecemMolecular imaging is devoted to the discovery
and application of specific biological imaging
approaches that complement traditional anatom-
ical imaging. This field continues to witness
impressive growth, particularly in the study of
oncology, neurology, and cardiovascular disease
(CVD). Interest in molecular imaging technolo-
gies stems from its great potential, not only to
heighten our understanding and diagnostic capa-
bility of common CVD scenarios, but also to offer
the prospect of personalized treatment and early
monitoring of therapeutic response. Targeted
imaging reporters are now spawning the devel-
opment of combined diagnostic and therapeutic
agents that can deliver therapy to individual cells
in affected tissues. Recently, diagnostic imaging
probes for myocardial infarction (MI), stem cell
tracking, and atherosclerotic vascular disease have
demonstrated significant advances in preclinical
research and development (also see the Online
Appendix). Clinical molecular imaging studies
have further expanded into the areas of aortic
dissection and aneurysm disease, and have pro-
vided new insights into aspects of heart failure
and transplant medicine. In this review, we high-
light outstanding CVD molecular imaging stud-
ies published over the past year. A summary of
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Clinical Investigations
A major goal of molecular imaging is to foster
translation of innovative technology into the
clinical arena. Clinical molecular imaging stud-
ies of human atherosclerosis remain prominent.
In addition, new strategies have been devel-
oped for imaging myocardial disease, as well
other areas of vascular disease.
Atherosclerosis
The overarching goal of atherosclerosis molecular
imaging is to identify features associated with
at-risk (vulnerable) plaques that are prone to
rupture. Such plaques may harbor inflammation,
hemorrhage, thrombus, neovascularization, or
apoptotic cells, aspects suitable for molecular
imaging. Studies investigating atherosclerosis
based on 18-fluorodeoxyglucose (18F-FDG) pos-
tron emission tomography (PET) imaging of
laque metabolism/inflammation, and possibly
ypoxia, lead the efforts in clinical CVD molec-
lar imaging.
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31818F-FDG PET imaging of carotid plaque inﬂammation.
18F-FDG is a radiolabeled glucose analog trans-
ported into metabolically active cells, and its pres-
ence is correlated with plaque macrophage content.
18F-FDG PET imaging, therefore, is a surrogate
reporter of this critical cell involved in atherogenesis
and plaque rupture. On the basis of the commercial
availability of the 18F-FDG tracer and clinical PET
canners, 18F-FDG PET has become one of the most
idely employed clinical molecular imaging strategies
o study the presence and evolution of endovascular
nflammation, particularly in the larger arterial beds
i.e., carotid, aorta).
CAROTID PLAQUE INFLAMMATION AND RISK OF
MICROEMBOLI. Microemboli emanating from carotid
laques are associated with an increased risk of stroke, as
ell as larger macrophage-rich areas in carotid atheroma.
gents for Molecular Imaging of Cardiovascular Disease
Modality Primary Target
PET Glucose transporter-1, hexokin
CMR Macrophages
SPECT Annexin-A5/macrophages
Spectral CT Macrophages
PET  CMR Macrophages
SPECT Folate receptor/macrophages
CMR, NIRF Macrophages
esicles CMR, NIRF Macrophages
CMR Macrophages
CMR, NIRF Macrophages
CT Macrophages
NIRF Cysteine proteases
NIRF Matrix metalloproteinases
SPECT Matrix metalloproteinases
CMR Matrix metalloproteinases
rticles CMR, NIRF v3 integrins
SPECT v3 integrins
paramagnetic CMR CD13 aminopeptidase
SPECT Matrix metalloproteinases
CMR Fibrin
Spectral CT Fibrin
CMR GPIIb3 receptor/platelets
PET Benzodiazepine receptor/macr
NIRF Hydroxyapatite
PET Herpes simplex virus thymidin
beled leukocytes SPECT White blood cells
CMR Myeloperoxidase activity
glucose; CLIO  crosslinked iron oxide; CMR  cardiac magnetic resonance; cN
SV-tk  herpes simplex virus thymidine kinase; L-PLP  liposomal prednisolon
aphy; RIP  radiolabeled imaging peptide; SPECT  single-photon emission comn a cross-sectional study of 16 patients with recentnterior circulation transient ischemic attack or minor
troke and 50% to 99% ipsilateral carotid stenosis, 18F-
FDG PET imaging was performed (1). Carotid micro-
emboli signals (MES) were detected on transcranial
Doppler ultrasound (middle cerebral artery, 1-h dura-
tion, same day as PET imaging). 18F-FDG PET dis-
criminated between MES and MES plaques (p 
0.005) on the basis of their degree of local inflammation.
Notably, plaque percent stenosis did not provide discrim-
inatory power between MES and MES plaques in
the pilot study (p  0.48). Prospective studies are
indicated to determine whether 18F-FDG PET imaging
f carotid plaque inflammation/metabolism will improve
isk prediction of stroke beyond percent stenosis derived
rom anatomical imaging.
PLAQUE INFLAMMATION AND CARDIOVASCULAR
RISK FACTORS. Extending the application of 18F-
Application Clinical
Atherosclerosis, aneurysm (metabolism) Yes
Atherosclerosis (inﬂammation) Yes
Atherosclerosis, myocardial infarction
(apoptosis)
Yes
Atherosclerosis (inﬂammation) No
Atherosclerosis (inﬂammation) No
Atherosclerosis (inﬂammation) No
Atherosclerosis (inﬂammation) No
Atherosclerosis (inﬂammation) No
Atherosclerosis (inﬂammation) [Theranostic] No
Atherosclerosis (inﬂammation) [Theranostic] No
Atherosclerosis (inﬂammation) No
Atherosclerosis (inﬂammation) No
Atherosclerosis (inﬂammation) No
Atherosclerosis (inﬂammation) No
Atherosclerosis, aneurysm (inﬂammation) No
Atherosclerosis (neovascularization) No
Myocardial infarction (ﬁbrosis) Yes
Myocardial infarction (neovascularization) No
Aneurysm, myocardial infarction, vascular
injury (inﬂammation)
No
Thrombosis (coagulation) Yes
Thrombosis (coagulation) No
Thrombosis (platelet activity) No
ages Vasculitis (inﬂammation) Yes
Valvular disease (calciﬁcation) No
ase Stem cell therapy (cell tracking) No
Heart failure/transplant (inﬂammation) Yes
Heart failure/transplant (oxidative stress) No
cyclic Asn-Gly-Arg; CT  computed tomography; Gd  gadolinium; HDL 
osphate; MPO  myeloperoxidase; NIRF  near-infrared ﬂuorescence; PET 
d tomography; USPIO  ultrasmall superparamagnetic iron oxide.Table 1. Promising A
Agent
18F-FDG ase
USPIO
99mTc-annexin A5
Au-HDL
CLIO-64Cu
99mTc-EC20
Apoferritin cages
Synthetic Gd anionic v
L-PLP
CLIO-THPC-AF750
N1177
ProSense
MMPsense
99mTc-RP805
P947
v3-targeted nanopa
99mTc-RIP
cNGR peptide–labeled
quantum dot
111In-RP782
EP-2104R
NanoK
P975
[11C]-PK11195 oph
OsteoSense
HSV-tk e kin
99mTc-exametazime–la
MPO-Gd
18F-FDG  18-ﬂuorodeoxy GR 
high-density lipoprotein; H e phFDG PET imaging to patients with diabetes mel-
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319litus, Kim et al. (2) studied 90 age- and sex-
matched subjects without known cardiovascular
disease, who were divided evenly between normal,
impaired glucose tolerance, and type 2 diabetes.
Images revealed that carotid artery 18F-FDG up-
ake increased incrementally with the degree of
lucose intolerance, and the mean and maximum
laque target-to-background ratios (TBRs) corre-
ated with several cardiovascular risk factors and
etabolic biomarkers. The same subjects stratified
y Framingham Risk Scores of10%, 10% to 20%,
nd 20% also showed increasing maximum TBRs
f 1.2, 2.0, and 2.3, respectively, (p  0.001).
nterestingly, however, concomitantly obtained ca-
otid intima-media thicknesses were similar among
ll 3 groups, providing further evidence that inflam-
ation cannot be routinely evaluated using structural-
ased imaging approaches.
RELATIONSHIP BETWEEN CAROTID PLAQUE IN-
FLAMMATION AND PLAQUE ECHOGENICITY. The
ssociation between carotid plaque ultrasound
chogenicity and 18F-FDG PET inflammation was
evaluated prospectively in 33 patients with symp-
tomatic carotid arterial disease (3). Although echo-
genic lesions demonstrated minimal 18F-FDG up-
take, echolucent atheroma, a putative ultrasound
marker of vulnerable carotid plaques, exhibited a
wide range of 18F-FDG–assessed inflammation.
Plaque inflammation in vivo correlated positively
with CD68 macrophages on endarterectomy his-
topathology specimens (r  0.501). Therefore,
within a range of suspected high-risk plaques
based on echolucency, 18F-FDG PET may fur-
her stratify at-risk lesions by their degree of local
nflammation. Stated another way, this study
hows that all echolucent plaques are not in-
amed. In addition, similar to other studies,
tenosis was not significantly associated with the
egree of plaque inflammation, or with plaque
chogenicity.
PLAQUE INFLAMMATION AND NEW BIOMARKERS.
In a validation study, Yoo et al. (4) positively
correlated elevated circulating blood adipocyte fatty
acid binding protein with carotid 18F-FDG PET
uptake in a cross-sectional study of 87 men without
previously diagnosed CVD or diabetes. Multiple
regression analysis accounting for other CVD risk
factors further identified adipocyte fatty acid bind-
ing protein as an independent predictor of 18F-FDG–
etermined vascular inflammation. This study dem-
nstrates the ability of molecular imaging strategies to
alidate potential biomarkers in human subjects. cNATURAL HISTORY OF 18F-FDG PET INFLAMMATION
SIGNALS. A prospective study has demonstrated
he stability of 18F-FDG plaque signal over a
-week period; however, longer-term data are lim-
ted. In a retrospective study, Menezes et al. (5)
xamined the records of 50 patients that had at least
PET/computed tomography (CT) scans per-
ormed over a mean follow-up period of 27 months.
he authors measured aortic and carotid 18F-FDG
ET uptake, as well as CT-determined Hounsfield
nit tissue density (i.e., calcification). Notably, no
nitial 18F-FDG–positive site remained positive on
ubsequent PET studies, suggesting that inflamma-
ion in a particular plaque may not persist for years.
rospective studies are needed to better understand
he natural history of plaque inflammation, and
hese data may arise from ongoing serial imaging
rials assessing the inflammatory-modulating effects
f new pharmacotherapeutics.
18F-FDG PET imaging of coronary plaque inﬂammation.
A noninvasive method to detect coronary arterial
inflammation could be highly useful. Major chal-
lenges for 18F-FDG PET imaging include relatively
ow spatial resolution and high background signal
rom metabolically active myocardium underlying
he coronary bed. Encouragingly, there has been
ecent progress in this area, aided by dietary ma-
ipulations that can suppress background myocar-
ial 18F-FDG signal.
CORONARY PLAQUE INFLAMMATION IN PATIENTS
WITH ACUTE CORONARY SYNDROMES AND STABLE
ANGINA. Rogers et al. (6) examined ascending aorta
nd left main coronary artery 18F-FDG PET uptake
n 25 patients 1 to 2 weeks after presenting with acute
oronary syndrome (ACS) or stable angina. In the left
ain coronary artery, greater 18F-FDG–based in-
ammatory activity was present in subjects with
CS compared with stable angina (Fig. 1) (plaque
BR: 2.48 vs. 2.00, p  0.03). In stented epicardial
oronary artery segments, similar findings were
bserved, with plaque TBRs in ACS patients
igher than those with stable angina (TBR: 2.61 vs.
.74, p  0.02). Impressively, 96% of coronary
ET segments were analyzable after dietary-based
uppression of background myocardial signal, in-
luding 89% of stented culprit lesions. The results
emonstrate that hybrid molecular PET/CT may
ave utility for noninvasive evaluation of left main
oronary arterial inflammation, as the left main is
arger, more remote from myocardium, and less
obile, leading to improved image quality and
o-registration with coronary CT angiography.
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320LEFT ANTERIOR DESCENDING ARTERIAL INFLAMMA-
TION. In an attempt to extend 18F-FDG to the
roximal coronary arteries, Saam et al. (7) examined
18F-FDG uptake in the proximal left anterior
descending coronary artery (LAD) in a consecutive
series of oncology patients. The authors found a
modest, but significant, correlation with various
cardiac risk factors (R  0.2), and further noted
hat patients with a TBR in the upper tertile had a
arger calcified plaque burden and higher pericardial
at volume than patients in the lower tertile. How-
ver, LAD data from 45% of the patients were not
sable due to background myocardial 18F-FDG
ptake, limiting image analysis. Further advances,
ossibly such as electrocardiogram-based triggering
f CT acquisitions, are needed to extend 18F-FDG
reliably into the non–left main coronary tree.
Statin pharmacotherapy and 18F-FDG PET plaque
ctivity. The effect of increasing statin dose on
18F-FDG PET atheroma uptake was prospectively
evaluated in 30 coronary artery disease patients
Figure 1. Co-Registered 18F-FDG PET/CT Imaging of Inﬂammatio
(A) In a patient with an acute coronary syndrome (ACS), the left main
deoxyglucose (18F-FDG) uptake. (B) A patient with stable angina and r
18F-FDG signal. Note also the focal 18F-FDG signal in the mixed compo
patient with stable angina shows comparatively modest 18F-FDG activ
with acute coronary syndrome. In panels A to D, the dashed arrow id
the stented region. CT  computed tomography; PET  positron emissiorandomized to atorvastatin 5 mg versus 20 mg daily i(8). All patients were scheduled for percutaneous
coronary intervention to treat stable angina symp-
toms, and none of them had received lipid-lowering
medications for at least the previous 12 months.
The day after percutaneous coronary intervention,
baseline 18F-FDG PET/CT imaging was per-
formed, and the 18F-FDG activity in the aorta and
emoral artery quantified. The patients were then
andomized to high- or low-dose statin therapy,
ith a follow-up 18F-FDG PET imaging study
performed 6 months later. The arterial 18F-FDG
BR was significantly reduced in the high-dose
tatin arm (aorta baseline TBR: 1.15 vs. 1.05, p 
.007; femoral baseline TBR: 1.12 vs. 1.02, p 
.012). Although there were similar significant
eductions in low-density lipoprotein and high-
ensitivity C-reactive protein levels in both the
igh-dose and the low-dose statin groups, the
ow-dose group did not show significant changes in
rterial 18F-FDG uptake. This suggests that higher
tatin doses may be required to reduce plaque
Human Coronary Arteries
) coronary artery and culprit stented lesion show enhanced 18-ﬂuoro-
t percutaneous coronary intervention reveals less stented segment
n LM coronary artery plaque. (C) A lesion stented months earlier in a
D) 18F-FDG uptake at the LM coronary artery trifurcation in a patient
es the LM coronary artery and, when present, the solid arrow points to
mography. Reproduced, with permission, from Rogers et al. (6).n in
(LM
ecen
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ity. (
entiﬁnflammation.
w
c
i
t
i
v
(
R
t
7
o
R
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 5 , N O . 3 , 2 0 1 2
M A R C H 2 0 1 2 : 3 1 7 – 2 8
Osborn and Jaffer
The Year in Molecular Imaging
321Near-infrared ﬂuorescence imaging of carotid plaque
protease activity. Augmented inflammatory pro-
tease activity is a marker of vulnerable plaques.
Using near-infrared fluorescence (NIRF) imaging
systems in concert with protease-activatable NIRF
imaging agents, Kim et al. (9) investigated ex vivo
matrix metalloproteinase and cysteine protease ac-
tivity in samples obtained from 56 subjects under-
going either carotid endarterectomy or carotid
stenting with filter devices. On macroscopic NIRF
imaging, enhanced cathepsin B and MMP 2/9
protease activity were identified both in retrieved
emboli and in bifurcations of carotid endarterec-
tomy specimens (Fig. 2). Plaques demonstrated
unstable histopathological features (rupture with
thrombus, hemorrhage, and thin, inflamed cap).
Symptomatic patients (ipsilateral stroke within 1
month) harbored plaques with greater protease
activity compared with asymptomatic patients. In-
triguingly, cathepsin B protease activity was dimin-
ished in patients taking statins, consistent with the
anti-inflammatory properties associated with this
medication class. Protease signal correlated mod-
estly with anatomic stenosis or ultrasound echolu-
cency, a suggested marker of plaque instability,
indicating that protease-identified inflammation
likely provides independent, complementary data
on plaque stability. Although NIRF molecular im-
aging agents are not yet approved for clinical study,
the current data, along with a recent report of a
clinical targeted fluorescence imaging trial (10),
provide momentum for future clinical testing of
NIRF protease sensors in human subjects.
Myocardial Infarction
Following irreversible myocardial damage, necrotic
muscle is replaced by collagen-dense scar that may
promote maladaptive tissue remodeling, myocardial
dysfunction, and clinical heart failure and malig-
nant arrhythmias. Typically, the true degree of
dysfunction and scar burden are not fully realized
until months after the index event, at a time when
there may be little reversibility. Therefore, early
detection of these changes may allow subsequent
intervention to prevent adverse outcomes.
Single-photon emission computed tomography im-
aging of ﬁbrogenesis post-MI, and its relationship to
ﬁnal infarct size at 1 year. In 10 patients presenting
ith MI, Verjans et al. (11) serially evaluated
hanges in interstitial extracellular matrix via an
ntravenous injection of an integrin receptor–
argeted arginine-glycine-aspartic acid–radiolabeledmaging peptide (RIP). RIP has been shown pre-
iously to target up-regulated integrin expression
e.g., v3) found on myofibroblasts that manufac-
ture collagen. At 3 and 8 weeks post-MI, 99mTc-
IP–enhanced single-photon emission computed
omography (SPECT) imaging revealed uptake in
0% of patients involving the infarct zone identified
n myocardial perfusion imaging. Importantly,
IP-based SPECT signal typically extended be-
Figure 2. NIRF Imaging of MMP and Cysteine Protease Activity
Resected Human Carotid Plaques
(A) Matrix metalloproteinase (MMP) near-infrared ﬂuorescence (NIRF
colocalizes with hemorrhagic, ulcerated carotid plaque regions (line
but is only weakly present in uncomplicated segments without the
(line 4). Of note, similar MMP activity is present in echolucent (line
and echogenic locations (line 3) identiﬁed by duplex ultrasonograp
(Duplex U.S.). (B) Tissue immunohistochemistry (IHC) at representat
regions corresponding with lines 1 to 4 in A reveal enhanced CD68
macrophage content that colocalizes with MMP-9 immunoreactivity
roscopic MMP activity on NIRF imaging. (Inset) MMP-9 staining at t
labeled by a hash mark not apparent in the low power view is evid
higher magniﬁcation. (C) MMP-2 immunoreactive regions overlap w
MMP-9 (compare the regions labeled with an asterisk and a hash m
and C). (D and E) MMP-9 colocalizes with MMP activity on NIRF mic
The arrowhead in B identiﬁes the location of the magniﬁed region
E. White scale bars  5 mm; black scale bars  2 mm; blue scale
200 m. Cy5.5 F-micro cyanine 5.5 ﬂuorescence microscopy; Intrain
) signal
s 1 to 3),
se features
s 1 and 2)
hy
ive
 (CD-68)
and mac-
he region
ent at
ith that of
ark in B
roscopy.
in D and
bars 
-OP intraoperative. Reproduced, with permission, from Kim et al. (9).
t
c
v
o
9
s
m
u
(
p
n
n
(
c
s
a
c
a
c
s
r
W
c
p
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 5 , N O . 3 , 2 0 1 2
M A R C H 2 0 1 2 : 3 1 7 – 2 8
Osborn and Jaffer
The Year in Molecular Imaging
322yond the fixed perfusion defect. At 1-year follow-
up, the pattern of early myocardial RIP uptake was
observed to be similar to the final infarct size as
measured by cardiac magnetic resonance (CMR)
late gadolinium enhancement (Fig. 3). RIP im-
aging early after infarction may therefore predict
the final extent of post-MI myocardial scarring,
and offer opportunities for earlier intervention.
Heart FailureandTransplantMedicine
Sarcoid cardiomyopathy and inﬂammation imaging
by 18F-FDG PET. Congestive heart failure is a wide-
reaching condition and a leading cause of hospital-
ization and death. Sarcoid cardiomyopathy is a
relatively uncommon, but important, cause of heart
failure that may be successfully treated if detected
early. Tahara et al. (12) studied cardiac inflamma-
tion in 24 patients with systemic sarcoid disease, of
which half had recognized cardiac involvement by
endomyocardial biopsy or clinical criteria. Com-
pared with healthy normal subjects or age-matched
controls with dilated cardiomyopathy, fasting 18F-
FDG uptake in cardiac sarcoidosis patients showed
significantly more heterogeneous myocardial signal.
Heterogeneity was quantified by the coefficient of
variation, defined as the 18F-FDG standard devia-
Figure 3. Clinical SPECT 99mTc-RIP Imaging of Myoﬁbroblast Ac
Myocardial Fibrosis at 1 Year
(Top) In 2 different patients, scar in the left anterior descending co
linium-enhanced cardiac magnetic resonance (CMR) at 1 year. (Mid
similar views for the same patients months earlier, with yellow arro
emission computed tomography (SPECT)/CMR fusion images are sh
VLA  vertical long axis. Reproduced, with permission, from Verjans etion divided by the mean uptake in a 17-segment
ardiac model. At a cutoff coefficient of variation
alue of 0.18, this metric demonstrated excellent
perating characteristics, with 100% sensitivity and
7% specificity. Following corticosteroid therapy,
erial repeat 18F-FDG PET assessment over 12
onths follow-up confirmed that the 18F-FDG
ptake variation returned to that of control subjects
Fig. 4). Thus, 18F-FDG PET imaging might
rovide useful diagnostic and treatment responsive-
ess in patients with sarcoid cardiomyopathy.
Detecting infected left ventricular assist devices us-
ing integrated SPECT/CT of leukocyte foci. The
oninvasive diagnosis of left ventricular assist device
LVAD) infection, a potentially life-threatening
ondition, remains challenging. Imaging modalities
uch as CT or magnetic resonance imaging (MRI)
re limited due to metallic artifacts and contraindi-
ations. A noninvasive imaging approach may avoid
dditional testing and treatment that in certain
ases may be costly and unnecessary. Furthermore,
uch an imaging approach could help assess the
esponse to antibiotic therapy in the LVAD itself.
ithin this context, Litzler et al. (13) performed a
linical cellular imaging study in 8 consecutive
atients with suspected LVAD infection, using
y 3 Weeks Post-MI, With Follow-Up CMR-Measured
ry artery distribution (yellow arrows) is identiﬁed with late gado-
99mTc-radiolabeled imaging peptide (RIP) uptake (blue arrows) in
placed for comparison to the CMR-identiﬁed scar. Single-photon
in the bottom row. MI  myocardial infarction; SA  short axis;tivit
rona
dle)
ws
ownal. (11).
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32399mTc-exametazime–labeled radioactive leukocytes
(99% viability with 90% labeling efficacy) and
hybrid SPECT/CT imaging. At 4 and 24 h after
injection of the radiolabeled autologous leukocytes,
pockets of infection were identified in all patients.
Images discriminated superficial from deep infec-
tion, and depicted the extent of LVAD involvement
and any remote involved sites. On the basis of the
location and severity of the 99mTc-labeled leukocyte
uptake, the duration of antibiotic therapy could be
effectively tailored, with follow-up scans in 5 sub-
jects demonstrating infection resolution in the
LVAD or in a non–LVAD-related source.
AorticDisease
Abdominal aortic aneurysm. Inflammation and
weakening of the vessel wall may lead to frank
rupture, especially in aneurysms that rapidly expand
or reach a critical size. New molecular imaging
methods are being directed to evaluate aneurysm
markers of instability such as inflammation, hem-
orrhage, and neovascularization.
CMR OF MACROPHAGES IN AORTIC ANEURYSM.
Fourteen patients with infrarenal abdominal aortic
aneurysm (4.0- to 5.5-cm diameter) underwent
Figure 4. Serial Cardiac 18F-FDG PET Imaging in Cardiac Sarcoid
(A) Compared with the strong baseline signal heterogeneity (high C
tion of heterogeneous myocardial 18F-FDG activity (low COV). (B) A
heterogeneous 18F-FDG uptake. COV  coefﬁcient of variation; Rx 
mission, from Tahara et al. (12).CMR of aneurysm inflammation following intrave-nous injection of Sinerem (ferumoxtran, Guerbet,
Villepinte, France) 2.6 mg Fe/kg, an ultrasmall
superparamagnetic iron oxide (USPIO) nanoparticle
agent phagocytosed by resident macrophages (14).
Compared with pre-USPIO injection, post-injection
CMR aneurysm signals were significantly lower
in macrophage-rich atherosclerotic areas. If vali-
dated prospectively, USPIO-enhanced CMR
could identify high-risk subjects with aneurysm
inflammation more likely to expand or rupture,
motivating increased surveillance and/or earlier
treatment.
A similarly sized study by Nchimi et al. (15)
detected biologically active macrophages within in-
traluminal thrombi of abdominal aortic aneurysms
via the superparamagnetic iron oxide (SPIO) agent
Endorem (ferumoxide, Guerbet, Villepinte, France).
Compared with USPIO, SPIO have relatively
larger size and shorter circulation half-life due to
rapid hepatic clearance, restricting distribution to
luminal surface targets and other well-perfused
tissues. Exploiting these properties, SPIO local-
ized in leukocyte-dense intraluminal thrombi 1 h
after injection, much earlier than the 24 to 36 h
necessitated by longer-circulating USPIOs. Ex
Patients
), a patient treated with corticosteroids reveals complete resolu-
treated patient at a similar follow-up time point exhibits more
eatment; other abbreviations as in Figure 1. Reproduced, with per-osis
OV
n un
trvivo CMR and histopathology of excised surgical
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324specimens obtained within 2 weeks of in vivo
imaging confirmed thrombus inflammatory cell
infiltration with iron particle retention, as well as
elevated matrix metalloproteinase 9 (MMP-9)
enzymatic activity.
Aortic dissection. Disruption of the aortic wall is a
life-threatening event that often requires immediate
surgical intervention. However, autopsy series indi-
cate that incidental aortic dissection is present in up
to 1% to 2% of subjects, suggesting that many
chronic aortic dissections can be managed conser-
vatively. Because anatomic imaging modalities do
not reliably distinguish acute from chronic dissec-
tions, new imaging strategies are needed.
18F-FDG PET IMAGING OF INFLAMMATION IN
ACUTE VERSUS CHRONIC AORTIC DISSECTION.
Reeps et al. (16) evaluated 18F-FDG PET imaging
to discriminate acute from chronic type B aortic
dissection in 18 patients. 18F-FDG enhancement
as observed at the injured aortic wall in all acute
issection patients 3 to 13 days after presentation
Fig. 5). Quantitative analysis revealed that the
tandardized uptake value (SUV) ratio, or TBR,
erformed significantly better in discriminating
cute from chronic stable dissection (SUV ratio:
.20 vs. 1.24, respectively, p  0.001) than simply
easuring maximum SUV at the site of injury,
hich suffered from false-negative and false-
ositive outliers. This preliminary study suggests
hat 18F-FDG PET may help distinguish acute
from chronic aortic dissection on the basis of the
degree of vessel wall inflammation.
18F-FDG AND AORTIC DISSECTION PROGNOSIS.
The prognostic value of 18F-FDG uptake in med-
ically managed acute aortic dissection was addressed
Figure 5. 18F-FDG PET Imaging of Arterial Wall Inﬂammation in
(A) Sagittal and (C) coronal hybrid PET/CT fusion images with corre
tions as in Figure 1. Reproduced, with permission, from Reeps et al. (16in 28 patients. PET scans were obtained approxi-
mately 2 weeks after CT diagnosis (17). All patients
had type B dissections except for 2 poor surgical
candidates with type A. Over 6 months, there were
8 unfavorable outcomes (death, surgical repair, or
dissection progression), predicted by the initial
inflammatory 18F-FDG uptake at the dissection
ite with an odds ratio of 7.72 for adverse events on
ultivariate analysis. 18F-FDG provided a sensitiv-
ity and specificity of 75% and 70%, respectively, for
mean SUV  3.029. Furthermore, in patients with
favorable outcomes, a lower 18F-FDG uptake corre-
sponded to a greater likelihood of dissection healing or
regression. These results provide intriguing prelimi-
nary evidence that 18F-FDG PET imaging may
risk-stratify aortic dissection populations that benefit
from aggressive earlier surgical intervention.
Vasculitis. Giant cell arteritis and Takayasu ar-
teritis are large-vessel inflammatory diseases that
can result in arterial occlusion, thrombosis, an-
eurysm, and accelerated atherosclerosis. New ap-
proaches are needed to understand the pathogen-
esis of these diseases in vivo.
PET IMAGING OF MACROPHAGES IN VASCULITIS
USING [11C]-PK11195. Pugliese et al. (18) tested the
PET imaging probe [11C]-PK11195, an established
human neuroimaging agent that selectively binds
the benzodiazepine receptor on activated macro-
phages. Six patients with giant cell arteritis or
Takayasu arteritis were compared with 9 asymp-
tomatic controls. Symptomatic subjects exhibited
enhanced [11C]-PK11195 signal on vascular PET
cans (TBR: 2.41 vs. 0.98 for asymptomatic pa-
ients, p  0.001). In 1 patient treated with 20
eeks of corticosteroid therapy, a follow-up [11C]-
7-Year-Old Male With an Acute Type B Aortic Dissection
ding (B) sagittal and (D) coronal CT reconstructions. Abbrevia-a 3
spon
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325PK11195 PET scan demonstrated markedly re-
duced vascular PET signal (TBR decreased from
1.63 to 0.87), associated with symptomatic im-
provement and decreased inflammatory biomarkers.
Compared with 18F-FDG, which reports on all
etabolically active cells, [11C]-PK11195 PET
may provide a more macrophage-specific readout,
given its ligand selectivity. In addition, [11C]- or
[18F]-PK11195 may also improve coronary athero-
sclerosis PET imaging of inflammation, because
background uptake by metabolically active myocytes
should be lower than in 18F-FDG PET imaging.
Advances in Preclinical Imaging Approaches
Atherosclerosis
In the last year, new atherosclerosis-targeted imag-
ing agents and devices have been developed to sense
plaque inflammation, angiogenesis, and oxidative
stress. In vivo studies of pharmacotherapeutic effi-
cacy, as well as the area of integrated therapeutic
and diagnostic targeted imaging (“theranostics”),
particularly via nanotechnological approaches, are
also in a growth phase.
Inﬂammatory macrophages. Macrophages are piv-
otal cells in atherogenesis, driving plaque expansion
and plaque complications. Macrophages are the
most established imaging target for atherosclerosis
molecular imaging studies, with clinical detection of
plaque macrophages enabled by 18F-FDG PET and
USPIO-enhanced CMR. Although these ap-
proaches have proven valuable, new reporter agents
are diversifying imaging platforms and aiming to
improve sensitivity.
PET AGENTS. The positron emitter [11C]-PK11195
has been studied to image activated macrophages in
clinical vasculitis, as discussed in the previous text.
11C-choline, a source of cell membrane lipids found
in high levels in proliferating cells, including plaque
macrophages (19), was shown to colocalize with
murine plaques by autoradiography, and was able to
distinguish noninflamed and inflamed, macrophage-rich
plaques (20). A head-to-head comparison with
18F-FDG may be informative in understanding any
potential advantages with respect to achievable
TBRs.
SPECT AGENTS. Folate receptor beta is expressed
n activated macrophages and thus offers another
olecular imaging target for atherosclerosis. The
PECT tracer 99mTc-labeled folate-targeted probe
(99mTc-EC20) was investigated in murine athero-
clerosis (21). In vivo SPECT imaging demon-trated greater SPECT signal in animals on a
igh-cholesterol diet compared with a regular chow
iet. Uptake of 99mTc-EC20 was also reduced in
animals treated with clodronate liposomes, a mac-
rophage apoptosis–inducing therapeutic agent.
Whether the additional macrophage specificity
conferred by a folate receptor–based SPECT ap-
proach is advantageous compared with 18F-FDG
emains to be tested in clinical subjects.
CMR AGENTS. Based on the natural affinity of
macrophages for ferritin, targeted imaging agents
comprised of bioengineered polypeptide apoferritin
(iron-free ferritin) cages were developed as NIRF or
CMR agents by coupling apoferritin to the NIR
fluorochrome cyanine 5.5 or to magnetite nanopar-
ticles, respectively (22). In diabetic, high-fat diet–
fed mice, the imaging agents localized to the
macrophage-rich lesions of ligated carotid arteries.
Loading of other imaging agents or even therapeu-
tic drugs into the apoferritin protein cage architec-
ture is possible, providing versatility for this
macrophage-avid agent.
Maiseyeu et al. (23) synthesized gadolinium-
containing anionic vesicles comprised of phosphati-
dylserine and a novel synthetic oxidized cholesterol
ester derivative that avidly binds low-density lipopro-
tein. Reporter vesicles were internalized by macro-
phages via scavenger receptors in culture, and in rabbit
atheroma in vivo, as shown by 1.5-T CMR. This
liposomal agent can also be formulated with fluores-
cently labeled lipids, and has potential advantages for
a good safety profile, easy manufacturing, and scalabil-
ity that could facilitate clinical testing.
DUAL-MODAL PET-MRI REPORTERS. Extending
rior work with PET-MRI high-resolution/high-
ensitivity macrophage reporters based on 64Cu-
labeled crosslinked iron oxide (CLIO-64Cu), Jarrett
et al. (24) tested CLIO-64Cu, as well as
adolinium/64Cu-labeled maleylated bovine serum
albumin for targeting of the macrophage scavenger
receptor A (SRA). Macrophages in injured carotid
arteries in 3 different rodent models were visualized
with both 64Cu-based PET reporters, as well as by
7-T MR (T1-weighted for gadolinium-based
agents, T2-weighted for CLIO-based agents) for
higher-resolution imaging.
CT AGENTS. Although coronary CT imaging has
demonstrated substantial clinical utility, few molec-
ular imaging agents are available for CT platforms.
Using a high-density lipoprotein (HDL)-based
macrophage-targeted gold nanoparticle coupled
with spectral (“multicolor”) CT, a multienergy im-
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326aging approach based on the discrimination of x-ray
energy attenuation differentials, Cormode et al. (25)
imaged plaque macrophages in apoE/ mice. Cap-
talizing on the multispectral capabilities, in addition
o macrophage detection, simultaneous co-registered
mages of calcification (bones) and iodinated contrast
angiography) were obtained in the same mice (Fig. 6).
hese results expand the selection of current nanoparticle
T agents for macrophages (e.g., N1177), and may
ccelerate the use of CT as a molecular and anatomical
maging approach for coronary atherosclerosis.
Myocardial Infarction
Post-MI healing involves an orchestrated immune
response. Hypo- or hyperimmune cell infiltration
following MI can impair myocardial healing, and
may promote mechanical complications (rupture) or
adverse left ventricular (LV) remodeling (progres-
sive dilation). Methods to study key effector cells
and molecules in post-MI healing may shed impor-
tant insight into this process in vivo, and potentially
offer new therapeutic strategies.
Inﬂammation and myocardial healing. THE EFFECTS
OF HYPERLIPIDEMIA ON POST-MI INFLAMMATION
AND HEALING. In wild-type and apolipoprotein
E–negative (apoE/) hyperlipidemic mice, Panizzi
Figure 6. Thoracoabdominal Spectral CT Imaging of Murine Ath
(A–C) Spectral computed tomography (CT) images in an apolipopro
(D and E) Spectral CT images in the aortic bifurcation after co-injec
tein. Reproduced, with permission, from Cormode et al. (25).t al. (26) first quantified monocyte recruitment
ost-MI by mapping the pro- and anti-inflammatory
ubtypes Ly-6Chi and Ly-6Clo via flow cytometry.
ApoE/ mice showed significantly increased levels
of inflammatory Ly-6Chi monocytes, cells that
secrete degradative enzymes. Using noninvasive,
dual-channel fluorescence molecular tomogra-
phy–CT molecular imaging of post-MI mice (Fig. 7),
the authors found that in vivo inflammatory cathepsin
enzymatic activity (activatable agent ProSense680,
PerkinElmer, Waltham, Massachusetts) and mac-
rophage activity (reporter agent CLIO-750) was
also greater in apoE/ mice (26). Atherosclerotic
mice had 10-fold greater Ly-6Chi monocyte infil-
tration in the infarct zone 5 days post-MI than
wild-type controls, as assessed by histopathology,
and was associated with increased inflammatory
markers, proteolysis, and phagocytosis. In addition,
serial CMR showed that apoE/ mice with MI
eveloped greater ventricular dilation compared
ith wild-type mice, despite having similar infarct
izes initially. Furthermore, induction of Ly-6Chi
monocytosis alone by intraperitoneal lipopolysaccha-
ride injection in wild-type mice without hyperlipid-
emia or atherosclerosis recapitulated a similar post-MI
inflammatory state. This work concludes that the
sclerosis via the Gold-Based Nanoparticle Au-HDL
-negative (apoE/) mouse after Au-HDL injection 24 h earlier.
of Au-HDL and iodinated contrast. HDL  high-density lipopro-ero
tein
tion
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327Ly-6Chi monocyte may be a therapeutic cellular target
n the post-MI setting.
Please see the Online Appendix for additional
igh-impact preclinical imaging studies.
Outlook
Molecular imaging studies are shedding important
light on the cellular and molecular biology underlying
important cardiovascular diseases. Excitingly, this last
year witnessed a growth in clinical molecular investi-
gations, particularly in the areas of atherosclerosis,
aneurysm disease, and MI. In the short term, we
anticipate continued expansion of 18F-FDG PET–
ased molecular imaging applications of vascular dis-
ase. Insights from 18F-FDG PET should prove
seful in predicting which atherosclerosis therapeutics
ill likely be efficacious and safe. Across many areas of
VD, molecular imaging data studies will continue to
lucidate the in vivo pathogenesis of disease, and will
Figure 7. Noninvasive FMT/CT Dual-Target Molecular Imaging o
Control Mice
(A) Five days post MI, CT images reveal apical infarct (arrows). Corr
cence molecular tomography (FMT)/CT images of inﬂammatory acti
infarct macrophages) in control C57Bl/6 mice (top) and apoE/ m
rates the in vivo FMT/CT imaging results. *p  0.05. TBR  target-t
Reproduced, with permission, from Panizzi et al. (26).f key CVD events, such as acute plaque rupture and
dverse LV remodeling.
Due to lower imaging agent dose requirements,
ew strategies for PET and SPECT may be clini-
ally available in the next 2 years. In addition, select
uorescence agents may enter the clinical arena
ithin the next 1 to 3 years. These trends will
nable new clinical molecular imaging studies of
VD, and will be spurred further by advances in
linical imaging systems, especially in the emerg-
ng areas of fluorescence imaging and multispec-
ral CT imaging. As more agents transition from
he bench to the patient bedside, molecular imaging
tudies should prove helpful in the clinical manage-
ent of CVD.
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